SCM
LFCR icon

SG Capital Management’s Lifecore Biomedical LFCR Stock Holding History

SG Capital Management’s Portfolio LFCR Stock Details LFCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-144,613
Closed -$1.63M – 66
2021
Q2 		$1.63M Buy
+144,613
New +$1.67M 0.45% 51

Other funds holding LFCR

WC
Wynnefield Capital New York $148M AUM 32.71% 1-Year Est. Return
LPAM
Legion Partners Asset Management Los Angeles, California $138M AUM 53.69% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
CSC
Cove Street Capital El Segundo, California $76.6M AUM 36% 1-Year Est. Return
ICM
ISZO Capital Management New York $2M AUM 35.61% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
HA
Heartland Advisors Milwaukee, Wisconsin $1.96B AUM 28.26% 1-Year Est. Return
2L
22NW LP Seattle, Washington $146M AUM 29.83% 1-Year Est. Return
KCM
Kennedy Capital Management St Louis, Missouri $4.72B AUM 36.69% 1-Year Est. Return

SG Capital Management's LFCR Position: Q3 2021 in Review

SG Capital Management sold out of Lifecore Biomedical (LFCR) in Q3 2021, closing a stake of 144,613 shares — an estimated $1.63M sold.

SG Capital Management first reported a position in LFCR in Q2 2021 and held it in 1 quarter. The position peaked at $1.63M in Q2 2021. 92 funds tracked by Wall St. Rank hold LFCR as of Q3 2021.

  • SG Capital Management reported no remaining Lifecore Biomedical position as of Q3 2021 after selling out during the quarter.
  • SG Capital Management sold 144,613 Lifecore Biomedical shares in Q3 2021, an estimated $1.63M.
  • SG Capital Management first reported a position in Lifecore Biomedical in Q2 2021 and held it in 1 quarter.
  • SG Capital Management's Lifecore Biomedical position peaked at $1.63M in Q2 2021.
  • 92 funds tracked by Wall St. Rank held Lifecore Biomedical as of Q3 2021.

Based on SG Capital Management's 13F filing for Q3 2021, filed 18 Oct 2021.